BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20

• 

  Patents

  Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors

  An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.

  February 18, 2026

   · 

  4 min read

   · 

  Shawna Williams
• 

  Rare diseases

  Ionis Paves Its Own Path as Initial Tryngolza Launch Defies Expectations

  Long an R&D company that partnered off assets, RNAi biotech Ionis Pharmaceuticals shifted in 2025 to bring two medicines to market alone. Analysts are already impressed—and there’s more to come in 2026.

  February 18, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Career Advice

  When Senior Leaders Are Asked To Carry Too Much

  With leaner teams and tighter budgets, senior leaders can face tremendous strain as they juggle increased workloads and leadership responsibilities. In this column, Kaye/Bassman’s Michael Pietrack discusses how pressure builds and what can ease it.

  February 18, 2026

   · 

  5 min read

   · 

  Michael Pietrack
• 

  Layoff Tracker

  Concerto Downsizes Amid Pivot to Consumers; Faraday Closes Down

  Follow along as BioSpace tracks job cuts and restructuring initiatives.

  February 18, 2026

   · 

  55 min read

   · 

  BioSpace Editorial Staff
• 

  Collaboration

  Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline

  CSL is advancing clazakizumab for the treatment of cardiovascular events in end-stage kidney disease and will retain rights over the asset in this indication. Lilly will explore other conditions.

  February 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Legal

  Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

  Arbutus alleges that Moderna’s COVID-19 vaccine infringes on patents protecting its lipid nanoparticle delivery technology.

  February 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Alzheimer’s disease

  Korsana Joins Alzheimer’s Amyloid Arena With $150M Debut, Next-Gen Antibody

  Korsana’s lead program uses a next-generation shuttling technology to improve delivery into the brain and lower the incidence of amyloid-related imaging abnormalities.

  February 18, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Venture capital

  Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook

  PitchBook’s 2025 biopharma VC analysis clocked $33.8 billion in capital dispatched in 2025, mainly to companies with later-stage programs ready to roll into the clinic.

  February 18, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  FDA

  FDA Reverses Course on Moderna’s mRNA Flu Shot Application, Promising August Decision

  The disagreement between Moderna and the FDA has reached a resolution just eight days after the biotech received a Refusal-to-File letter in response to its application for mRNA-1010. Moderna will now seek approval of the vaccine based on age.

  February 18, 2026

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Opinion

  Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk

  Regulatory uncertainty is no longer background noise. It is a material investment risk that reshapes how capital is deployed and pipelines are prioritized.

  February 18, 2026

   · 

  6 min read

   · 

  Harris Kaplan